MDMA shows promise for the treatment of post-traumatic stress disorder. Combining the use of Ecstasy with psychotherapy treatments resulted in a reduction of PTSD symptoms after just one session. 54% of the study participants no longer met the PTSD criteria after two sessions. Patients also reported improvements in depression symptoms.
Using a unique mouse model, researchers show cognitive deficits associated with schizophrenia may be reversible.
A new study reveals a psychostimulant prescribed for ADHD increases glutamate in the brains of healthy people, resulting in more positive emotions.
A new study reveals ADHD increases the risk of sexually transmitted infections in adolescents threefold compared to the general population. However, the use of ADHD medications reduces the risk of STIs in males by up to 41%.
Ezogabine, an FDA approved anti-convulsant, appears to significantly reduce symptoms in those with major depressive disorder.
Fenofibrate, a drug developed to control cholesterol, alleviated brain and behavioral abnormalities in mouse models of schizophrenia.
Ketamine may improve brain functions involved in mood regulation, researchers report.
A new Nature Communications study reports the antidepressant Clomipramine may relieve symptoms of primary progressive multiple sclerosis.
A new small scale study reveals the antidepressant fluvoxamine may be a new tool in the fight against COVID-19. Researchers report fluvoxamine reduced the severity of coronavirus symptoms and hospitalizations.
Researchers believe the newly understood mechanism could yield insights into more precise future treatments for nerve pain and depression.